326 related articles for article (PubMed ID: 9772934)
1. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
Amabile G
Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
[TBL] [Abstract][Full Text] [Related]
2. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
5. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
6. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
Verdecchia P; Angeli F; Pittavini L; Gattobigio R; Benemio G; Porcellati C
Ital Heart J; 2004 Jul; 5(7):505-10. PubMed ID: 15487267
[TBL] [Abstract][Full Text] [Related]
7. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular hypertrophy as a risk factor in hypertension.
Balogun MO; Dunn FG
Afr J Med Med Sci; 1996 Sep; 25(3):277-83. PubMed ID: 10457806
[TBL] [Abstract][Full Text] [Related]
9. [Regression of left ventricular hypertrophy in hypertensive heart disease].
Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
[TBL] [Abstract][Full Text] [Related]
10. [Cardiac failure in hypertensive cardiopathy].
Verdecchia P
Ital Heart J; 2000 Jun; 1 Suppl 2():72-7. PubMed ID: 10905132
[TBL] [Abstract][Full Text] [Related]
11. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide.
Lokhandwala Y; Damle A
Curr Med Res Opin; 2004 May; 20(5):639-44. PubMed ID: 15140328
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
[TBL] [Abstract][Full Text] [Related]
14. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
[TBL] [Abstract][Full Text] [Related]
15. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
Messerli FH; Ketelhut R
J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
19. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
Agabiti-Rosei E
Blood Press Suppl; 1997; 2():13-5. PubMed ID: 9495620
[TBL] [Abstract][Full Text] [Related]
20. The assessment of left ventricular hypertrophy in hypertension.
Alfakih K; Reid S; Hall A; Sivananthan MU
J Hypertens; 2006 Jul; 24(7):1223-30. PubMed ID: 16794466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
